Surrozen (NASDAQ:SRZN) versus Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Critical Analysis

Surrozen (NASDAQ:SRZN) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.

Valuation and Earnings

This table compares Surrozen and Swedish Orphan Biovitrum”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48 million	106.34	-$242.03 million	($40.55)	-0.79
Swedish Orphan Biovitrum	$2.89 billion	6.30	$48.85 million	$2.01	25.40

Swedish Orphan Biovitrum has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Surrozen and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-112.29%
Swedish Orphan Biovitrum	20.67%	17.92%	9.30%

Analyst Ratings

This is a breakdown of recent ratings for Surrozen and Swedish Orphan Biovitrum, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1	1	5	1	2.75
Swedish Orphan Biovitrum	0	3	5	0	2.62

Surrozen presently has a consensus price target of $61.75, suggesting a potential upside of 93.72%. Given Surrozen’s stronger consensus rating and higher probable upside, analysts clearly believe Surrozen is more favorable than Swedish Orphan Biovitrum.

Institutional and Insider Ownership

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Surrozen has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.

About Surrozen

Surrozen, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation. The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.